Assessment of Antibiotic Resistance in Escherichia coli
DOI:
https://doi.org/10.69667/lmj.2517325Keywords:
Escherichia coli, Urinary Tract Infections, and Antimicrobial Resistance.Abstract
Escherichia coli is the most common cause of urinary tract infections (UTIs) and has shown increasing resistance to widely used antibiotics. Resistance assessment is crucial for guiding clinical therapies and public health measures. This cross-sectional study was conducted on 30 E. coli isolates obtained from urine samples of patients attending clinics. Antimicrobial susceptibility testing was performed against 10 commonly prescribed antibiotics using the disk diffusion test. High resistance was detected to azithromycin and fusidic acid (70% each) and to amoxicillin (66.6%). Cefotaxime (30%) and amikacin (50%) showed significant resistance. Ciprofloxacin (16.6%), levofloxacin and ceftriaxone (13.3% each), and meropenem (3.3%) showed lower levels of resistance. The most sensitive antibiotics were levofloxacin (86.7%), ceftriaxone (86.7%), and meropenem (96.7%). E. coli isolates exhibited considerable resistance to several commonly used antibiotics, particularly azithromycin, fusidic acid, and amoxicillin. However, meropenem and third-generation cephalosporins retained strong activity. These findings underscore the importance of ongoing antimicrobial resistance surveillance and rational antibiotic prescribing to maintain treatment efficacy.
References
Watt AE, Cummins ML, Donato CM, Wirth W, Porter AF, Andersson P, et al.; Australian Pathogen Genomics One Health Working Group. Parameters for one health genomic surveillance of Escherichia coli from Australia. Nat Commun. 2025 Jan 2;16(1):17. doi: 10.1038/s41467-024-55103-2. Erratum in: Nat Commun. 2025 Apr 7;16(1):3309. PMID: 39747833.
Bangash K, Mumtaz H, Mehmood M, Hingoro MA, Khan ZZ, Sohail A, et al. Twelve-year trend of Escherichia coli antibiotic resistance in the Islamabad population. Ann Med Surg (Lond). 2022 May 27;78:103855. doi: 10.1016/j.amsu.2022.103855. PMID: 35734722.
Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010 Dec;7(12):653-60. doi: 10.1038/nrurol.2010.190. PMID: 21139641.
Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Aust Prescr. 2019 Feb;42(1):14-9. doi: 10.18773/austprescr.2019.002. PMID: 30765904.
Frieri M, Kumar K, Boutin A. Antibiotic resistance. J Infect Public Health. 2017 Jul-Aug;10(4):369-78. doi: 10.1016/j.jiph.2016.08.007. PMID: 27616769.
Elsayah K, Atia A, Bkhait N. Antimicrobial resistance pattern of bacteria isolated from patients with urinary tract infection in Tripoli city, Libya. Asian J Pharm Health Sci. 2017;7(4).
Almshawit H, Shagshog R, Aldib H, Areebi S, Tahar W. Antimicrobial Resistance Patterns of Escherichia coli Among Visitors of Pathology Centers in Gharyan. Alq J Med App Sci. 2025 Feb 24:345-51.
Cantas L, Suer K, Guler E, Imir T. High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus. Front Microbiol. 2016 Jan 13;6:1446. doi: 10.3389/fmicb.2015.01446. PMID: 26793167.
Versporten A, Coenen S, Adriaenssens N, Muller A, Minalu G, Faes C, et al.; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997-2009). J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi13-23. doi: 10.1093/jac/dkr454. PMID: 22096062.
Kasanga M, Shempela DM, Daka V, Mwikisa MJ, Sikalima J, Chanda D, et al. Antimicrobial resistance profiles of Escherichia coli isolated from clinical and environmental samples: findings and implications. JAC Antimicrob Resist. 2024 Apr 27;6(2):dlae061. doi: 10.1093/jacamr/dlae061. PMID: 38680604.
Kuti JL, Wang Q, Chen H, Li H, Wang H, Nicolau DP. Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints. Infect Drug Resist. 2018 May 25;11:783-90. doi: 10.2147/IDR.S161636. PMID: 29872328.
Ivanova M, Mészáros J, Kureljušić J, Žutić M, Milovanović M, Kehrenberg C, et al. Azithromycin resistance in Escherichia coli and Salmonella from food-producing animals and meat in Europe. J Antimicrob Chemother. 2024 Jul 1;79(7):1657-67. doi: 10.1093/jac/dkae143. PMID: 38757599.
Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2015 Aug;59(8):4544-50. doi: 10.1128/AAC.00753-15. PMID: 25987639.
Sharma B, Chalikwar R, Bhalerao S, Gondane AA, Pawar D, Sharma A. Cefotaxime Versus Ceftriaxone: A Comprehensive Comparative Review. Cureus. 2024 Sep 11;16(9):e69146. doi: 10.7759/cureus.69146. PMID: 39398799
